Lightnews — Scholar-powered news

Reposted by Michelle Yong

Dr.D Restrepo @drdrestrepo.bsky.social · Sep 1

Interesting!

Michelle Yong @michyong.bsky.social · Sep 1

🔥🔥Just published in #CID world-first clinical trial of IFN-a nasal spray vs placebo reduced #COVID 🦠 incidence 📉 by 40% in cancer pts. Well tolerated, safe, effective…

Full link here: academic.oup.com/cid/advance-ar…

5 7

Reposted by Michelle Yong

Denis - The COVID Info Guy @thecovidinfoguy.bsky.social · Aug 30

Study: Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial.

Published: 28 August 2025

Source: academic.oup.com/cid/advance-...

Journal Article Corrected proof Editor's Choice
Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial Open Access
Michelle K Yong , Karin Thursky , Megan Crane , Tim Spelman , Robert K Mahar , Julie A Simpson , Andrew M Scott , Simon J Harrison , Jeff Szer , Marc Pellegrini ... Show more
Author Notes
Clinical Infectious Diseases, ciaf409, https://doi.org/10.1093/cid/ciaf409
Published: 28 August 2025 Article history

4 12 44

Reposted by Michelle Yong

Denis - The COVID Info Guy @thecovidinfoguy.bsky.social · Aug 30

Australian-led trial shows nasal spray reduces COVID-19 risk in cancer patients.

"The research... showed that a nasal spray containing interferon-alpha (IFN-α), a naturally occurring protein with broad antiviral activity, could reduce the risk of COVID-19 infection by 40% compared to placebo."

Australian-led trial shows nasal spray reduces COVID-19 risk in cancer patients - Peter MacCallum Cancer Centre

www.petermac.org

5 51 180

Reposted by Michelle Yong

Don Vinh @donvinh.bsky.social · Aug 31

With COVIDhge, we previously ✍🏼 about IFN therapy for COVID, based on findings that 🧬mutations or auto-Abs to type I IFN caused severe COVID.
Now, an RCT shows this concept extends more broadly👇🏼

Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients academic.oup.com/cid/article/...

Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial

In this randomized, double-blind, placebo-controlled trial, 433 participants received daily nasal spray 40 000 IU IFN-α or placebo for 3 months. The primar

academic.oup.com

1 7

Reposted by Michelle Yong

UW Infectious Disease Fellowship Program @uwidfellowship.bsky.social · Sep 4

In this RCT, 433 adults w/cancer randomized to daily IFN-alpha or placebo nasal spray. Incidence of COVID was significantly different at 8.3% w/ IFN-alpha vs 14.4% in control, w/ no difference in other resp viruses (similar in vaccinated subgroup)… #IDSky

academic.oup.com/cid/advance-...

Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial

In this randomized, double-blind, placebo-controlled trial, 433 participants received daily nasal spray 40 000 IU IFN-α or placebo for 3 months. The primar

academic.oup.com

1 2

Michelle Yong @michyong.bsky.social · Sep 1

🔥🔥Just published in #CID world-first clinical trial of IFN-a nasal spray vs placebo reduced #COVID 🦠 incidence 📉 by 40% in cancer pts. Well tolerated, safe, effective…

Full link here: academic.oup.com/cid/advance-ar…

1 3 17

Reposted by Michelle Yong

NCICancer @ncicancer.bsky.social · May 9

Day 2 of the @petermaccc.bsky.social Research Symposium opened with A/Prof @michyong.bsky.social plenary on "Transforming the care of Infectious Diseases in Cancer Patients." Discussing groundbreaking research and future directions in fungal, viral, bacterial, and vaccine clinical trials.

1 4

Reposted by Michelle Yong

Priya Garg @priyagargiddoc.bsky.social · May 15

Grateful to have received a travel stipend to spend an exciting few days at the @fredhutch.bsky.social ICH Symposium in Seattle, present & learn from experts in the field- Including @kottonnelson.bsky.social, Jay Fishman & our own @ncicancer.bsky.social @michyong.bsky.social, Monica Slavin & more..!

1 2 11

Reposted by Michelle Yong

NCICancer @ncicancer.bsky.social · Apr 12

Prof Monica Slavin at the meet the experts on Mycology clinical trials- have you participated?#escmidglobal

1 1 2

Reposted by Michelle Yong

NCICancer @ncicancer.bsky.social · Apr 8

We are excited for #ESCMIDGLOBAL - the premier event for Infectious Diseases and Microbiology hosted by @escmid.bsky.social in Vienna, Austria! 🌍
If you're planning to attend, we’d love to connect with you. Below are the details of our presentations, including titles, times, and locations.

2 3 4

Reposted by Michelle Yong

Priya Garg @priyagargiddoc.bsky.social · Apr 4

Honoured to speak & present our @ncicancer.bsky.social work on infection prevention in cancer/transplant at the Australasian Society of ID ASM with @nikhil-singh.bsky.social @michyong.bsky.social @benwteh.bsky.social, & amazing to hear & see the incredible work done at other centres nationally 👏🏽

2 2 8

Reposted by Michelle Yong

NCICancer @ncicancer.bsky.social · Apr 1

Join A/Professor @michyong.bsky.social this Thursday 3rd of April at 10 am ET, for the @ichs-global.bsky.social Early Career virtual networking session to connect, collaborate, and shape the future of Early Career programs!

To learn more and sign up: ichs.wildapricot.org/page-1863364

International Immunocompromised Host Society - Early Career Session

ichs.wildapricot.org

1 3

Reposted by Michelle Yong

NCICancer @ncicancer.bsky.social · Apr 3

Great 1st day at Australasian Society for Infectious Diseases meeting!

@michyong.bsky.social led an insightful CMV symposium

@benwteh.bsky.social chaired the "What's New in.." session as part of ICHSIG

@priyagargiddoc.bsky.social comprehensive talk on key developments and gaps in the ICHS space

2 5

Reposted by Michelle Yong

Europe PMC @europepmc.org · Jan 28

Hello, Bluesky!👋 We are excited to connect with you!🌟
Europe PMC is an open database of global life science research - discover articles, preprints, theses, grants, and more. We talk about scholarly communication, open science, bioinformatics, and meta research. Follow us and join the conversation!

Trusted research on Europe PMC: Access a free collection of biomedical research: 45M articles and preprints with 10M as full text.

Research links on Europe PMC: Explore connected research with links to open data, peer reviews, protocols and more.

Developer tools on Europe PMC: Innovate with resources for developers, from open APIs to training datasets and ML models.

Europe PMC is a trusted platform: Supported by 35 funders, developed by EMBL-EBI and partner with PubMed Central.

3 80 170

Reposted by Michelle Yong

Australian Society for Antimicrobials @ausantibiotics.bsky.social · Feb 22

Kicking off the #pharmacysymposium
We have @michyong.bsky.social highlighting the use of marabivir in tricky #ID populations #CMV and real world use beyond the clinical trials. (With promising clinical effectiveness) #antiviralstewardship
#antimicrobials2025

3 6

Reposted by Michelle Yong

Nico Barros @nicobarrosid.bsky.social · Feb 21

If it's written by @kottonnelson.bsky.social, it is a must read!

Concise expert insight into the utility of Immune monitoring assays for Cytomegalovirus.

journals.lww.com/transplantjo...

Immune Monitoring Assays: Predicting Cytomegalovirus and... : Transplantation

An abstract is unavailable.

journals.lww.com

2 10

Michelle Yong @michyong.bsky.social · Feb 21

Thanks @sonkoning.bsky.social . We’ve learnt so much over the years… more promising therapies to come

Sonia Koning @sonkoning.bsky.social · Feb 21

What’s on the horizon for COVID for immunocompromised patients? Monoclonals, interferon nasal spray, T-cell therapy @michyong.bsky.social #antimicrobials2025 #ASA

1

Michelle Yong @michyong.bsky.social · Feb 21

What a great meeting! @ausantibiotics.bsky.social

NCICancer @ncicancer.bsky.social · Feb 21

#ASA2025 in Melbourne! 🌟
@michyong.bsky.social discussed alternative antiviral treatments for COVID-19. Last night, Prof Karin Thursky delivered the prestigious Howard Florey Oration, and today, A/Prof Gabrielle Haesuler led the 'Year in Review' session. Inspiring moments from our leaders!

1 3

Reposted by Michelle Yong

NCICancer @ncicancer.bsky.social · Feb 21

#ASA2025 in Melbourne! 🌟
@michyong.bsky.social discussed alternative antiviral treatments for COVID-19. Last night, Prof Karin Thursky delivered the prestigious Howard Florey Oration, and today, A/Prof Gabrielle Haesuler led the 'Year in Review' session. Inspiring moments from our leaders!

1 4

Reposted by Michelle Yong

NCICancer @ncicancer.bsky.social · Feb 11

Happy International Women in Science Day!

With over 85% of our cohort being women, we are dedicated to promoting, supporting, and strengthening women in science!

Discover the achievements of these women here:
cancerandinfections.org/phd-pathways

@michyong.bsky.social @abbydouglas.bsky.social

1 6

Reposted by Michelle Yong

Priya Garg @priyagargiddoc.bsky.social · Feb 2

Really interesting paper by my colleagues at @domucla.bsky.social - and fits with my own thoughts about the utility/pitfalls of plasma mcfDNA (including low yield of fungal pickup) as well as giving some ideas for future diagnostic stewardship if incorporated into practice @jschaenmanmd.bsky.social

Real-world clinical impact of plasma cell-free DNA metagenomic next-generation sequencing assay | Infection Control & Hospital Epidemiology | Cambridge Core

Real-world clinical impact of plasma cell-free DNA metagenomic next-generation sequencing assay

www.cambridge.org

2 2 10

Michelle Yong @michyong.bsky.social · Jan 18

Congratulations Tori!

Tori Hall @victoriahall.bsky.social · Jan 16

Very proud of this hard work & team effort from all involved! Limited benefit of adjuvanted flu 💉 & 2 vs 1 dose in pts w/ MM, CLL or NHL. @ncicancer.bsky.social @petermaccc.bsky.social @benwteh.bsky.social @trubianojason.bsky.social @michyong.bsky.social @nejm.org www.nejm.org/doi/full/10....

Influenza Vaccination Strategies in Patients with Hematologic Cancer | NEJM

In this trial involving patients with hematologic cancers, the immune responses that were elicited were similar for adjuvanted-dose and standard-dose influenza vaccines.

www.nejm.org

1 1

Reposted by Michelle Yong

Steven Pergam, MD, MPH @pergamic.bsky.social · Nov 18

New virtual meeting for Immunocompromised Host Society: Addressing the Landscape of CMV Management in Transplant Recipients. Free to members or $25 plus a free membership for those not already members!

Forward on to your residents, fellows, grad students, and international colleagues

#TxID #CMV

2 10 14

Michelle Yong @michyong.bsky.social · Nov 17

Thanks @germhuntermd.bsky.social ! Wow the ICH #TxID group is growing by the day. Just updated and followed - thanks for making it easier to find our friends and colleagues.

Ilan Schwartz @germhuntermd.bsky.social · Nov 16

Welcome @michaelisonmd.bsky.social to #TxID and #IDSky!

Here is a starter pack to help you find the ol' gang go.bsky.app/95rzmLi

And here is a link to a feed you can pin that will index all Skeets (yes that's what we call them) tagged with TxID bsky.app/profile/did:...

1 1 7

Michelle Yong @michyong.bsky.social · Nov 16

Australian adoption paperwork is underway @kottonnelson.bsky.social !Love these photos!

Camille Nelson Kotton @kottonnelson.bsky.social · Nov 15

Loving my time in Melbourne as the Forbes Fellow. Such a great city. Awesome parks and green space. Love the flat whites! Gorgeous birds of paradise, always reminds me of my mom - her favorite flowers. Feel very lucky to be part of such a great medical community for a week!!

1 4